We read with great interest the prospective observational study by Otremba et al, 1 which shows that use of proton-pump inhibitors (PPIs) is one of independent factors associated with development of delirium in geriatric inpatients (odds ratio [OR] =1.67; confidence interval [CI] =1.11-2.53; P=0.014). We especially appreciate their new finding, because PPIs are commonly prescribed in older hospitalized patients. However, we found two points worthy of discussion and we would like to share our perspectives in the following paragraphs.
Dear editor
We read with great interest the prospective observational study by Otremba et al, 1 which shows that use of proton-pump inhibitors (PPIs) is one of independent factors associated with development of delirium in geriatric inpatients (odds ratio [OR] =1.67; confidence interval [CI] =1.11-2.53; P=0.014). We especially appreciate their new finding, because PPIs are commonly prescribed in older hospitalized patients. However, we found two points worthy of discussion and we would like to share our perspectives in the following paragraphs.
Firstly, Fujii et al reported that delirium incidence was significantly higher in patients receiving histamine-2 receptor antagonists (H2RA) than in patients receiving PPIs (OR=3.82; CI=1.15-12.71, P=0.047) and they suggested that switching gastric acid inhibitors from H2RA to PPIs could provide an appropriate coping method for drug-induced delirium. 2 Otremba et al's study will drive clinicians to pay more attention to pharmacotherapeutic monitoring of neuropsychiatric complication during PPI treatment duration.
Secondly, although Otremba et al discussed the mechanism behind the PPI and geriatric delirium association from multiple perspectives including a very brief mention of potential drug-drug interaction (DDI) between PPI and other drugs (eg, benzodiazepines and antidepressants), they did not demonstrate more details on the DDI aspect. Herein, we would like to further discuss it. Different from other benzodiazepines, diazepam is susceptible to cytochrome P450 2C19 (CYP2C19) inhibition. 3 We have shown that different PPI has different risk of CYP2C19-mediated DDI and omeprazole has a greater risk for DDI with diazepam compared with other PPIs (eg, esomeprazole, pantoprazole, lansoprazole, and rabeprazole). 4, 5 So it is worthy to investigate the association of omeprazole versus other PPIs with delirium risk in geriatric inpatients receiving diazepam. Antidepressants also exhibit different risk of DDIs with PPIs. The effect of co-medicated PPIs on the serum concentration of selective serotonin reuptake inhibitors is more pronounced for omeprazole and esomeprazole than for lansoprazole and pantoprazole, whereas escitalopram, rather than citalopram and sertraline, is more susceptible to omeprazole and esomeprazole. 6 Therefore, inappropriate drug combinations of PPI-benzodiazepine or PPI-antidepressants is an element worthy of consideration when evaluating specific factors for development of delirium in elderly patients.
In their letter, Ling-ling Zhu and Quan Zhou added several new perspectives concerning our recently published study on delirium risk factors in the geriatric ward and specifically gastric acid inhibitors as independent risk factors. We share the opinion that increased vigilance is warranted when prescribing proton-pump inhibitors (PPIs) and monitoring their adverse reactions. PPIs are considered more effective than histamine-2 receptor antagonists and relatively safe. [1] [2] [3] Consequently, these medications are prescribed for elderly patients at an increasing rate, frequently as long-term medication without evidence-based indications. 4 In our study population, 25% of patients were treated with PPIs while very few were treated with histamine-2 receptor antagonists. Increased use has revealed a more comprehensive adverse effect profile of PPIs, 5 which includes potential risk factors for delirium in elderly patients. We also agree that PPI in-class differences, not analyzed in our paper, should be considered in future studies as well as taken into account in clinical practice.
